Anchen Pharmaceuticals Inc., Axcan, Cephalon, Teva, Impax, Mylan musculoskeletal news

The U.S. District Court for the District of Delaware issued a temporary restraining order enjoining Mylan from manufacturing, using, offering to sell or selling a generic version of muscle relaxant Amrix cyclobenzaprine pending an appeal by Cephalon of an earlier decision in which the court found two patents covering Amrix from Eurand N.V. and Cephalon were invalid due to obviousness. In 2008 and 2009, Eurand and Cephalon filed six lawsuits against Impax, Teva's Barr Pharmaceuticals Inc. subsidiary, Mylan and Anchen claiming their ANDAs for a generic version of Amrix infringed U.S. Patent Nos. 7,387,793 and 7,544,372 covering Amrix XR and Amrix, respectively (see BioCentury, April 18). ...